- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00362414
Beta-hCG + Erythropoietin in Acute Stroke (BETAS)
August 16, 2016 updated by: Steven C. Cramer, MD, University of California, Irvine
Safety of Beta-hCG + Erythropoietin in Acute Stroke
The purpose of this study is to assess the safety of Beta-hCG + Erythropoietin in patients with acute ischemic stroke.
Study Overview
Detailed Description
Patients with a new stroke will be evaluated at the University of California Irvine Medical Center (UCIMC), a JCAHO-certified Stroke Center, and at Hoag Memorial Hospital Presbyterian.
Standard stroke pathways will be used to identify such patients and to initiate standard of care therapy.
Patients potentially eligible for study enrollment will be identified, screened, then consented and enrolled.
Those meeting all entry criteria, and no exclusion criteria, will undergo additional baseline testing including brain MRI.
A 9-day course of B-E therapy will then begin, always within 48 hours after stroke onset.
This therapy will consist of hCG (3 once-daily IM doses at 10,000 IU per dose, one day apart, on days 1, 3 and 5 of study participation), followed by a one day washout period (day 6), followed by Epo (three once-daily i.v.
doses at 30,000 IU per dose on days 7, 8, and 9 of study participation).
Patients will be examined at several time points during therapy, as well as 6 weeks and 3 months after stroke onset.
The primary outcome measures are related to safety, while secondary outcome measures are related to disability, neurological status, and MRI measures.
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Orange, California, United States, 92868-4280
- University of California, Irvine Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 21-85
- NIHSS score 6-24 at time of enrollment, ensuring that stroke is neither mild nor devastating
- Stroke is ischemic in origin, supratentorial, and radiologically confirmed
- Patient is 24-48 hours from time of stroke onset at time that first dose of B-E therapy is administered. Time of onset is when symptoms began, and stroke occurred during sleep, time of onset is when patient was last seen to be normal.
- Reasonable expectation of availability to receive the full 9 day B-E therapy course
- Reasonable expectation that patient will receive standard post-stroke physical, occupational, speech, and cognitive therapy as indicated
Exclusion Criteria:
- Pre-existing and active major psychiatric or other neurological disease
- History of significant alcohol or drug abuse in the prior 3 years
- Serum hemoglobin > 16 g/dL in a male patient or > 14 g/dL in a female patient; or a platelet count > 400,000/mm3 in either a male or female patient
- Advanced liver, kidney, cardiac, or pulmonary disease; the former will be operationally defined as a serum bilirubin > 4 mg/dL, alkaline phosphatase > 250 U/L, SGOT > 150 U/L, SGPT >150 U/L, or creatinine > 3.5 mg/dL
- Pregnancy or lactating; note that a negative pregnancy test will be required if the patient is a female in reproductive years, using a test that reliably detects beta-hCG levels > 25 with normal levels being < 8 IU/L.
Contraindication to study participation on the basis of any of the following:
- Allergy or other contraindication to initiating either beta-hCG or Erythropoietin
- Known hypersensitivity to mammalian cell-derived products or hypersensitivity to albumin
- A known diagnosis of prostatic cancer; note that prostate specific antigen will be collected for retrospective assessment of safety, but will not be used to ascertain study eligibility
- Dysuria of unexplained origin
- Uncontrolled hypertension, defined in the context of acute stroke as blood pressure persistently above 220 mm Hg systolic or 120 diastolic despite antihypertensive therapy
- Current use of either beta-hCG or Erythropoietin
- Other condition known to elevate beta-hCG, active in the prior 24 months, e.g., choriocarcinoma or germ cell tumor
- Terminal medical diagnosis consistent with survival < 1 year
- Known hypercoagulable state, which for the purposes of this study will deficiency of proteins C, S, or antithrombin III; activated protein C resistance; prothrombin gene mutation; or an anti-phospholipid antibody syndrome as based on clinical and laboratory measures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dual Growth Factor
All patients received erythropoietin and beta-hCG.
This was the only treatment arm in the study, i.e., all enrollees received active therapy.
|
10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation 30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 3 mo
|
Safety through Day 90 was assessed through adverse event reporting, serial examinations, blood testing, and a leg vein Doppler at Day 42.
Number of participants who experienced adverse events, had abnormality in serial examinations, blood testing, and a leg vein Doppler at Day 42.
|
3 mo
|
Morbidity
Time Frame: 3 mo
|
attributable to experimental intervention
|
3 mo
|
Mortality
Time Frame: 3 mo
|
attributable to experimental intervention
|
3 mo
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Action Research Arm Test
Time Frame: 3 mo
|
The Action Research Arm Test is a 19 item measure divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement).
Performance on each item is rated on a 4-point ordinal scale ranging from: 3: Performs test normally 2: Completes test, but takes abnormally long or has great difficulty 1: Performs test partially 0: Can perform no part of test.
Total scores range from 0-57 points, a higher score being better with 57 being considered "normal".
|
3 mo
|
Fugl-Meyer Arm Scale
Time Frame: 3 mo
|
Fugl-Meyer arm scale is a measurement scale of the upper body with three sections being Proximal, Wrist/Hand, and Coordination/Speed.
The scores can range from 0-66 with a higher score being better.
A score of 66 is considered "normal" with no impairments.
|
3 mo
|
Fugl-Meyer Leg Scale
Time Frame: 3 mo.
|
Measure of leg motor impairment with three subsections which are Proximal, Hip/Knee, and Speed/Coordination.
The scale ranges from 0-34 with a higher score being better.
A score of 34 is considered "normal".
|
3 mo.
|
Boston Naming Test
Time Frame: 3 mo
|
Measure of aphasia or other language disturbance caused by stroke or other dementing disorders.
It consists of 60 line drawings graded in difficulty in which patients are to name each picture.
|
3 mo
|
Line Cancellation Test
Time Frame: 3 mo
|
Measure of spatial neglect where patients must cross out lines placed in a random orientation.
Missed lines may indicate areas of spatial neglect.
|
3 mo
|
NIH Stroke Scale
Time Frame: 3 mo
|
Measure of global impairment post stroke.
It includes 11 items to examine levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss.
The scoring scale is between 0-42 where a higher score is indicative of a more severe stroke.
|
3 mo
|
Geriatric Depression Scale Short Form
Time Frame: 3 mo
|
Measure of depression done as a self-report.
It is a series of 15 questions designed to be a screen for depression.
The scores range from 0-15 with a higher score being more indicative of depression.
|
3 mo
|
Barthel Index
Time Frame: 3 mo
|
Measure of disability in terms of performance of activities of daily living (ADL).
The scores range from 0-100 with a higher score being associated with a higher level of independence.
|
3 mo
|
Infarct Volume Using Anatomical MRI
Time Frame: 3 mo
|
Measurement of infarct volume and percent change from baseline to Day 90.
|
3 mo
|
Trail Making A Test
Time Frame: 3 mo
|
Measure of memory and executive function where one is asked to connect dots consecutively based on the number of the dot.
Test taker is allowed 2 minutes to connect the dots with a maximum score of 25 for all dots connected correctly.
|
3 mo
|
Trail Making B Test
Time Frame: 3 mo.
|
Measure of memory and executive function where one is asked to connect dots with letters and numbers alternating between number and letter and connecting dots consecutively.
Test taker is allowed 4 minutes to connect the dots with a maximum score of 25 for all dots connected correctly.
|
3 mo.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Steven C. Cramer, MD, MMSc, University of California, Irvine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2006
Primary Completion (Actual)
March 1, 2008
Study Completion (Actual)
March 1, 2008
Study Registration Dates
First Submitted
August 9, 2006
First Submitted That Met QC Criteria
August 9, 2006
First Posted (Estimate)
August 10, 2006
Study Record Updates
Last Update Posted (Estimate)
August 29, 2016
Last Update Submitted That Met QC Criteria
August 16, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS#2005-4800
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Cidat, S.A. de C.V.El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco SuarezUnknownStroke | Stroke, Acute | Cerebral Stroke | Cerebrovascular Stroke | Cerebrovascular Accident, AcuteMexico
-
Centre hospitalier de l'Université de Montréal...Not yet recruitingStroke, Acute ThromboticCanada
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
University Hospital, MontpellierNot yet recruiting
-
Capital Medical UniversityRecruitingAcute Stroke | Ischemic Stroke, AcuteChina
-
Chonbuk National University HospitalKorean Society of Neurosonology; Ministry of SMEs and Startups, Republic of... and other collaboratorsCompleted
-
National Taiwan University HospitalCompleted
-
University of EdinburghNHS LothianRecruiting
Clinical Trials on Dual Growth Factor
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnMalignant Neoplasm | Gastrointestinal Mucositis
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
Ege UniversityCompletedInfection | Healing Surgical Wounds
-
Institute of Dermatology, ThailandChumsaeng ChumsaengsriActive, not recruiting
-
Ege UniversityCompletedEdema | Postoperative Pain | TrismusTurkey
-
University of Nevada, RenoCompletedDepression, AnxietyUnited States
-
West China HospitalRecruitingBone Substitute | Concentrated Growth FactorChina
-
University of Nevada, RenoCompletedDepression, AnxietyUnited States
-
Beijing Tongren HospitalRecruiting
-
Martin, PaulNational Cancer Institute (NCI)CompletedPrimary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditionsUnited States